FRANKFURT & ESCHBORN, Germany--(BUSINESS WIRE)--Accovion, a leading European full-service Contract Research Organization, headquartered in Frankfurt (Eschborn), Germany, today announced that it has entered into a definitive agreement to be acquired by Clinipace Worldwide, a global digital Contract Research Organization (dCRO).
“We are pleased to join the Clinipace Worldwide organization,” says Dr. Andree Beckerling, the CEO of Accovion. “With the strong strategic alignment between Clinipace’s and Accovion’s capabilities, objectives and values, I am confident that Clinipace Worldwide is a great fit for our continued commitment to quality, reliability and flexibility.” Dr. Beckerling elaborates: “Clinipace Worldwide with global headquarters in Research Triangle Park, NC, USA, and operations in US, Europe, Asia and South Americas will benefit from the sizable add-on of Accovion's European presence with strong back-end and front-end services. Accovion clients gain access to Clinipace’s dCRO delivery model supported by their proprietary TEMPO™ eClinical platform. The combined European organization provides the right combination of complimentary operational strengths, services and geography and will further boost its strong regional position as a leading European full service CRO.”
Clinipace Worldwide uses technology as the foundation of its service offering. The company has pioneered an innovative service delivery model to address the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms. The innovative digital aspect of Clinipace Worldwide allows the combined company to provide a cutting-edge, proven technology platform to significantly improve oversight and performance of clinical trials.
“With Accovion we are able to improve our value proposition for the European market by significantly expanding our European geography and establishing all of the full-service clinical development and regulatory needs within local time zones via an integrated European unit with an excellent reputation and broad expertise,” states Jeff Williams, CEO of Clinipace Worldwide.
Dr. Beckerling will have day-to-day operating responsibility for all of the European offices, including existing Clinipace staff and locations. Together, Accovion and Clinipace Worldwide will now be home to nearly 400 staff in Europe and nearly 1,000 globally. The combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements.
Combined with Accovion, Clinipace now has operations and staff in 39 countries. European operations are based in Frankfurt, Munich and Marburg, Germany; Prague, Czech Republic; Krakow, Poland; Timisoara, Romania; Moscow, Russia; Zurich, Switzerland; Milan, Italy; Lyon, France; Madrid, Spain; London, United Kingdom and Kiev, Ukraine.
Please visit www.accovion.com for further information.
About Clinipace Worldwide
Clinipace Worldwide, a digital contract research organization (dCRO), pioneered an innovative, technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms.
therapeutic areas such as oncology, cardiovascular, and metabolic diseases, gastroenterology, infectious diseases, nephrology, immunology, and vaccines, the company assists life science firms in successfully executing regulatory strategies, clinical development, and post-approval research programs.
Clinipace Worldwide global headquarters are based in Research Triangle Park, NC with additional offices located across the globe in 39 countries including Asia, North and South America and Europe. For more information, visit http://www.clinipace.com.